SANES

10.482

-0.61%↓

BBVA

19.26

-0.57%↓

BNP

92.25

-1.09%↓

CABK

11.345

-0.44%↓

INGA

25.035

-0.85%↓

SANES

10.482

-0.61%↓

BBVA

19.26

-0.57%↓

BNP

92.25

-1.09%↓

CABK

11.345

-0.44%↓

INGA

25.035

-0.85%↓

SANES

10.482

-0.61%↓

BBVA

19.26

-0.57%↓

BNP

92.25

-1.09%↓

CABK

11.345

-0.44%↓

INGA

25.035

-0.85%↓

SANES

10.482

-0.61%↓

BBVA

19.26

-0.57%↓

BNP

92.25

-1.09%↓

CABK

11.345

-0.44%↓

INGA

25.035

-0.85%↓

SANES

10.482

-0.61%↓

BBVA

19.26

-0.57%↓

BNP

92.25

-1.09%↓

CABK

11.345

-0.44%↓

INGA

25.035

-0.85%↓

Home・Akciju saraksts・AB Science SA

AB Science SA

Slēgts

0.86 -2.93

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.86

Max

0.915

Galvenie mērījumi
By Trading Economics
Ienākumi	8.8M 3.6M
Pārdošana	144K 659K
Peļņas marža	549.317
Darbinieki	36
EBITDA	1.8M -727K

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2.4M 66M
Iepriekšējā atvēršanas cena	3.79
Iepriekšējā slēgšanas cena	0.86

AB Science SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. jūn. 23:49 UTC

Tirgus saruna

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

2026. g. 9. jūn. 23:45 UTC

Iegādes, apvienošanās, pārņemšana

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

2026. g. 9. jūn. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

2026. g. 9. jūn. 23:44 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

2026. g. 9. jūn. 23:43 UTC

Iegādes, apvienošanās, pārņemšana

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

2026. g. 9. jūn. 23:35 UTC

Tirgus saruna

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

2026. g. 9. jūn. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung: Additional Investment Makes It Largest Shareholder in Element

2026. g. 9. jūn. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

2026. g. 9. jūn. 20:51 UTC

Peļņas

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 9. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. jūn. 20:09 UTC

Tirgus saruna

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

2026. g. 9. jūn. 19:36 UTC

Tirgus saruna

Cattle Climbs as Crude Oil Falls -- Market Talk

2026. g. 9. jūn. 19:32 UTC

Tirgus saruna

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

2026. g. 9. jūn. 19:25 UTC

Tirgus saruna

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

2026. g. 9. jūn. 19:00 UTC

Tirgus saruna

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

2026. g. 9. jūn. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

2026. g. 9. jūn. 18:47 UTC

Tirgus saruna

No World Cup Inflation Seen So Far in Mexico -- Market Talk

2026. g. 9. jūn. 18:37 UTC

Tirgus saruna

Canada's Cooling Trade With the U.S. -- Market Talk

2026. g. 9. jūn. 18:27 UTC

Tirgus saruna

Precious Metals Lower as Trump Vows Military Response -- Market Talk

2026. g. 9. jūn. 17:35 UTC

Tirgus saruna

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

2026. g. 9. jūn. 17:30 UTC

Tirgus saruna

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

2026. g. 9. jūn. 16:34 UTC

Tirgus saruna

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. jūn. 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2026. g. 9. jūn. 15:28 UTC

Tirgus saruna

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

2026. g. 9. jūn. 15:25 UTC

Tirgus saruna

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Salīdzinājums

Cenas izmaiņa

AB Science SA Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AB Science SA — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.